Equine Herpesvirus-1 Consensus Statement

D.P. Lunn(Leeds Beckett University), Hugh G.G. Townsend(University of Saskatchewan), Nikolaus Osterrieder(Freie Universität Berlin), Nicholas Davis‐Poynter(The University of Queensland), Nicola Pusterla(University of California, Davis), D.W. Horohov(University of Kentucky), M. Julia B.F. Flaminio(Cornell University)
Journal of Veterinary Internal Medicine
May 1, 2009
10.1111/j.1939-1676.2009.0304.x
Cited by 303

Related Papers

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
|Cell|2020|387
Virus-induced senescence is a driver and therapeutic target in COVID-19
|Nature|2021|344
Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters
|Viruses|2020|243
Foals are interferon gamma-deficient at birth
|Veterinary Immunology and Immunopathology|2006|199
Report of the Second Equine Leucocyte Antigen Workshop, Squaw Valley, California, July 1995
|Veterinary Immunology and Immunopathology|1998|138